Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Orgenesis Inc (ORGS)

Orgenesis Inc (ORGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Orgenesis Inc 20271 Goldenrod Lane Germantown MD 20876 USA

www.orgenesis.com P: 480-659-6404

Description:

Orgenesis, Inc. is a biopharmaceutical company. It focused on developing its trans-differentiation technologies for diabetes. The company deals with the combination of cell-based therapy and regenerative medicine into clinical development. Its operating segment consists of Contract Development and Manufacturing Organization and Cellular Therapy Business. Contract Development and Manufacturing Organization segment activity includes MaSTherCell, which specializes in cell therapy development for advanced medicinal products. Cellular Therapy Business segment activity is based on its technology which demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell like insulin producing cells for patients with Type 1 Diabetes. Orgenesis, Inc. is headquartered in Germantown, MD.

Key Statistics

Overview:

Market Capitalization, $K 17,585
Enterprise Value, $K 45,915
Shares Outstanding, K 34,339
Annual Sales, $ 36,030 K
Annual Net Income, $ -14,890 K
Last Quarter Sales, $ 110 K
Last Quarter Net Income, $ -12,650 K
EBIT, $ -17,060 K
EBITDA, $ -15,080 K
60-Month Beta 1.07
% of Insider Shareholders 7.14%
% of Institutional Shareholders 22.56%
Float, K 31,887
% Float 92.86%
Short Volume Ratio 0.34

Growth:

1-Year Return -55.28%
3-Year Return -90.09%
5-Year Return -88.62%
5-Year Revenue Growth 93.09%
5-Year Earnings Growth 54.96%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.43 on 11/13/23
Latest Earnings Date 05/08/24
Earnings Per Share ttm -0.91
EPS Growth vs. Prev Qtr -186.67%
EPS Growth vs. Prev Year -760.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-12 on 11/16/17

ORGS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -590.97%
Return-on-Assets % -126.17%
Profit Margin % -41.33%
Debt/Equity 0.24
Price/Sales 32.97
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share 0.44
Interest Coverage -5.07
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar